Evidence map›Paper›PMID 42108351›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Fluorescent-Based Analysis of T Cells and T-Cell-Dependent Bispecific Antibody in a Brain Tumor Mouse Model.

Yuri Nakamura, Teppei Azuma, Masahiro Yasunaga

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuri NakamuraDivision of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Chiba, 277-8577, Japan.
Teppei AzumaDivision of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Chiba, 277-8577, Japan.
Masahiro YasunagaDivision of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Chiba, 277-8577, Japan. mayasuna@east.ncc.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell-dependent bispecific antibody (TDB) is a novel therapeutic antibody considered one of the promising immunotherapies for treating brain tumors. TDB activates T cells via CD3-mediated signaling by crosslinking CD3 expressed on T cells and tumor-associated antigens expressed on cancer cells. In preclinical studies, the efficacy of TDB targeting EGFRvIII, one of tumor-associated antigens, has been validated against malignant brain tumors. Despite its therapeutic potential, the in vivo dynamics of TDB and the T cells remain poorly understood. In this chapter, we describe a method to analyze the in vivo dynamics of TDB and T cells in brain tumor-bearing mice using fluorescence imaging.

Indexed as

Antibodies, BispecificBrain NeoplasmsOptical ImagingT-LymphocytesAnimalsCell Line, TumorDisease Models, AnimalHumansMiceXenograft Model Antitumor AssaysAntibodies, BispecificBrain tumorBrain tumor mouse modelCancer immunotherapyCell line-derived xenograft modelEx vivo imagingFluorescent imagingT-cell-dependent bispecific antibodies

Identifiers

PMID42108351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.